EGFR and brain neoplasm: In the future, SA-based PAMAM dendrimers co-loaded with medicinal drugs that target the specific proteins of brain tumors [e.g., integrins and epidermal growth factor receptor (EGFR)], have the potential to improve drug retention within tumors and to augment the medicinal effects.